NDASUBCUTANEOUSSOLUTION
Approved
Aug 2007
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
SOMATULINE DEPOT (lanreotide acetate) by Ipsen is lanreotide, the active component of somatuline depot is an octapeptide analog of natural somatostatin. First approved in 2007.
Drug data last refreshed 14h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SOMATULINE DEPOT is a subcutaneous somatostatin analog (lanreotide acetate) approved in 2007 for the treatment of acromegaly and neuroendocrine tumors. It works by mimicking natural somatostatin to inhibit growth hormone and other hormone secretion. The depot formulation provides extended-release delivery via intramuscular injection.
$53MPart D
LOE ApproachingEstablished revenue base with 5.4k annual claims suggests stable mid-tier franchise, but LOE-approaching status signals transition from growth to defensive positioning requiring strategic planning.
Mechanism of Action
Lanreotide, the active component of SOMATULINE DEPOT is an octapeptide analog of natural somatostatin. The mechanism of action of lanreotide is believed to be similar to that of natural somatostatin.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome
Started May 2009
115 enrolled
Carcinoid Syndrome
Career Relevance
242 linked roles indicate robust organizational footprint with broad functional opportunities spanning commercial, regulatory, and technical functions. Working on SOMATULINE DEPOT offers exposure to mature franchise management, market access strategy, and generic transition planning in endocrinology.
Director
Worked on SOMATULINE DEPOT at Ipsen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.